Tumor mutational burden as a predictive biomarker for response to immune checkpoint inhibitors: a review of current evidence
SJ Klempner, D Fabrizio, S Bane, M Reinhart… - The …, 2020 - academic.oup.com
Abstract Treatment with immune checkpoint inhibitors (ICPIs) extends survival in a
proportion of patients across multiple cancers. Tumor mutational burden (TMB)—the number …
proportion of patients across multiple cancers. Tumor mutational burden (TMB)—the number …
[HTML][HTML] Prognostic and predictive values of mismatch repair deficiency in non-metastatic colorectal cancer
Z Jin, FA Sinicrope - Cancers, 2021 - mdpi.com
Simple Summary A subset of colorectal cancers (CRCs) displays deficient DNA mismatch
repair (dMMR) that leads to microsatellite instability (MSI). These tumors have distinct …
repair (dMMR) that leads to microsatellite instability (MSI). These tumors have distinct …
Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers
AM Goodman, S Kato, L Bazhenova, SP Patel… - Molecular cancer …, 2017 - AACR
Immunotherapy induces durable responses in a subset of patients with cancer. High tumor
mutational burden (TMB) may be a response biomarker for PD-1/PD-L1 blockade in tumors …
mutational burden (TMB) may be a response biomarker for PD-1/PD-L1 blockade in tumors …
Microsatellite instability status determined by next‐generation sequencing and compared with PD‐L1 and tumor mutational burden in 11,348 patients
A Vanderwalde, D Spetzler, N Xiao, Z Gatalica… - Cancer …, 2018 - Wiley Online Library
Microsatellite instability (MSI) testing identifies patients who may benefit from immune
checkpoint inhibitors. We developed an MSI assay that uses data from a commercially …
checkpoint inhibitors. We developed an MSI assay that uses data from a commercially …
Microsatellite-stable tumors with high mutational burden benefit from immunotherapy
AM Goodman, ES Sokol, GM Frampton… - Cancer immunology …, 2019 - AACR
Abstract Programmed death receptor-1/ligand 1 (PD-1/L1) antibodies can induce durable
remissions in malignancies. However, response rates are only approximately 10% to 20% in …
remissions in malignancies. However, response rates are only approximately 10% to 20% in …
[HTML][HTML] ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy
R Okamura, S Kato, S Lee, RE Jimenez… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background Several cancer types harbor alterations in the gene encoding AT-Rich
Interactive Domain-containing protein 1A (ARID1A), but there are no approved therapies to …
Interactive Domain-containing protein 1A (ARID1A), but there are no approved therapies to …
Prevalence of PDL1 amplification and preliminary response to immune checkpoint blockade in solid tumors
AM Goodman, D Piccioni, S Kato, A Boichard… - JAMA …, 2018 - jamanetwork.com
Importance Copy number alterations in programmed cell death ligand 1 (PDL1orCD274),
programmed cell death 1 ligand 2 (PDCD1LG2orPDL2), and Janus kinase 2 (JAK2) genes …
programmed cell death 1 ligand 2 (PDCD1LG2orPDL2), and Janus kinase 2 (JAK2) genes …
[HTML][HTML] Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study
JK Sicklick, S Kato, R Okamura, H Patel, M Nikanjam… - Genome medicine, 2021 - Springer
Background Malignancies are molecularly complex and become more resistant with each
line of therapy. We hypothesized that offering matched, individualized combination therapies …
line of therapy. We hypothesized that offering matched, individualized combination therapies …
Analysis of DNA damage response gene alterations and tumor mutational burden across 17,486 tubular gastrointestinal carcinomas: implications for therapy
Background Alterations in the DNA damage response (DDR) pathway confer sensitivity to
certain chemotherapies, radiation, and other DNA damage repair targeted therapies …
certain chemotherapies, radiation, and other DNA damage repair targeted therapies …
Recent advances in the clinical development of immune checkpoint blockade therapy for mismatch repair proficient (pMMR)/non-MSI-H metastatic colorectal cancer
JJ Lee, E Chu - Clinical colorectal cancer, 2018 - Elsevier
Metastatic colorectal cancer (mCRC) continues to be associated with a poor prognosis, and
there remains a significant unmet need for novel agents and treatment regimens. Major …
there remains a significant unmet need for novel agents and treatment regimens. Major …